Delcath to Present at Canaccord Genuity 40th Annual Growth Conference

Rhea-AI Summary

Delcath Systems (NASDAQ: DCTH) announced that John Purpura, interim CEO, will present at the Canaccord Genuity 40th Annual Growth Conference on August 12, 2020, at 9 a.m. ET. A webcast of the presentation will be available for viewing. The company, renowned for its liver-directed treatments for cancers, is also engaging in one-on-one investor meetings. Delcath’s investigational product, Melphalan Hydrochloride for Injection, aims to deliver high-dose chemotherapy to the liver while minimizing systemic exposure. The system has not yet received FDA approval but is marketed in Europe as CHEMOSAT.

NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today announced that John Purpura, interim Chief Executive Officer, will be presenting virtually on Wednesday, August 12, 2020 at 9 a.m. ET in Track 5 at the Canaccord Genuity 40th Annual Growth Conference. A webcast of the presentation will be available at the following link: http://wsw.com/webcast/canaccord42/dcth/  

The Company will also be participating in one-on-one investor meetings. To schedule a meeting, please contact your Canaccord representative or email James@HaydenIR.com

About Delcath Systems, Inc.

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) – is designed to administer high-dose chemotherapy to the liver while minimizing systemic exposure and associated side effects. In addition to the Phase 3 FOCUS Trial, we have initiated a global Phase 3 clinical trial for intrahepatic cholangiocarcinoma (ICC) called The ALIGN Trial. We currently are also evaluating other forms of metastatic liver cancers.  Melphalan/HDS has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system is marketed under the trade name Delcath  CHEMOSAT® Hepatic Delivery System for Melphalan (CHEMOSAT) and has been CE Marked and used at major medical centers to treat a wide range of cancers of the liver. CHEMOSAT is being marketed under an exclusive licensing agreement with medac GmbH, a privately held multi-national pharmaceutical company headquartered in Germany that specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases.

Contact:

Hayden IR
James Carbonara
(646)-755-7412
james@haydenir.com 

Brett Maas
(646) 536-7331
brett@haydenir.com 

FAQ

When is Delcath Systems presenting at the Canaccord Genuity conference?

Delcath Systems will present on August 12, 2020, at 9 a.m. ET.

Who is the interim CEO of Delcath Systems?

John Purpura is the interim CEO of Delcath Systems.

What is the main focus of Delcath Systems?

Delcath Systems specializes in liver-directed treatments for primary and metastatic cancers.

What clinical trials is Delcath Systems currently involved in?

Delcath is conducting the Phase 3 FOCUS Trial and the ALIGN Trial for intrahepatic cholangiocarcinoma.

Is the Melphalan Hydrochloride product approved by the FDA?

No, Melphalan Hydrochloride for Injection has not been approved by the FDA for sale in the U.S.

What is CHEMOSAT?

CHEMOSAT is Delcath's system marketed in Europe for treating liver cancers, which has received CE Mark approval.